The Journal of Heart and Lung Transplantation
Volume 21, Issue 2 , Pages 204-210 , February 2002

Safety and efficacy of atorvastatin in heart transplant recipients

  • Devang N Patel, MD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • Francis D Pagani, MD

      Affiliations

    • Department of Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
    • ,
  • Todd M Koelling, MD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • David B Dyke, MD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • Ragavendra R Baliga, MD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • Robert J Cody, MD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • Kathleen D Lake, PharmD

      Affiliations

    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA
    • ,
  • Keith D Aaronson, MD, MS

      Affiliations

    • Corresponding Author InformationReprint requests: Keith Aaronson, University of Michigan Medical Center, Division of Cardiology, Room L3623, Ann Arbor, MI 48109-0271 USA Telephone: (734) 764-7440. Fax: (734) 615-3326
    • Cardiac Transplant Program, Department of Internal Medicine, Ann Arbor, Michigan, USA

Received 19 January 2001 ,Accepted 27 June 2001.

References 

  1. Eich D, Thompson JA, Ko D, et al.  Hypercholesterolemia in long-term survivors of heart transplantation (an early marker of accelerated coronary artery disease). J Heart Lung Transplant. 1991;10:45–49
  2. Esper E, Glagov S, Karp RB, et al.  Role of hypercholesterolemia in accelerated transplant vasculopathy (results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation). J Heart Lung Transplant. 1997;16:420–435
  3. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 1977;87:415–442
  4. Tanaka H, Sukhova GK, Libby P. Interaction of allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb Vasc Biol. 1994;14:734–745
  5. Shi C, Lee W, Russel M, et al.  Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation (studies in Apolipoprotein E knockout mice). Circulation. 1997;96:2722–2728
  6. Kobashigawa JA, Katznelson S, Laks H, et al.  Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621–627
  7. Wenke K, Meiser B, Thiery J, et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation (a four-year randomized trial). Circulation. 1997;96:1398–1402
  8. Kuo PC, Kirshenbaum JM, Gordon J, et al.  Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol. 1989;64:631–635
  9. Kobashigawa J, Murphy FJ, Stevenson LW, et al.  Low dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 1990;82(suppl IV):IV-281–IV-283
  10. Barbir M, Rose M, Kushwaha S, et al.  Low-dose simvastatin for the treatment of hypercholesterolemia in recipients of cardiac transplantation. Int J Cardiol. 1991;33:241–246
  11. Vanhaecke J, Van Cleemput J, Van Lierde J, et al.  Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation. 1994;58:42–45
  12. Pflugfelder PW, Huff M, Oskalns R, et al.  Cholesterol-lowering therapy after heart transplantation (a 12-month randomized trial). J Heart Lung Transplant. 1995;14:613–622
  13. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel II). JAMA. 1993;269:3015–3023
  14. Corpier CL, Jones PH, Suki WN, et al.  Rhabdomyolysis and renal injury with lovastatin use (Report of two cases in cardiac transplant recipients). JAMA. 1988;260:239–241
  15. Alejandro DS, Peterson J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol. 1994;5:152–160
  16. Anguita M, Alonso-Pulpón L, Arizón JM, et al.  Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pre-transplant atherosclerotic coronary artery disease. Am J Cardiol. 1994;74:776–779
  17. Ballantyne C. Statins after cardiac transplatation (which statin, what dose, and how low should we go?). J Heart Lung Transplant. 2000;19:515–517
  18. Kobashigawa JA, Moriguchi JD, Ro TK, et al.  Atorvastatin for refractory hypercholesterolemia in heart transplant recipients. JACC. 1998;31(2, supplement A):157A
  19. Magnani G, Carinci M, Magelli C, et al.  Role of statins in the management of dyslipidemia after cardiac transplant (Randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin). J Heart Lung Transplant. 2000;19:1710–2215
  20. Malinowski JM, Atorvastatin . A hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health. Syst Pharm. 1998;55:2253–2267
  21. Jones P, Kafonek S, Laurora , et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587
  22. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2–C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 1995;27:2397–2402
  23. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease. Lancet. 1994;344:1383–1389
  24. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  25. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect pravastatin on coronary events after myocardial infarction patients with average cholesterol levels. 1996;335:1001–1009
  26. Lewis SJ, Sacks FM, Mitchell JS, et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction. J Am Coll Cardiol. 1998;32:140–146
  27. Downs JR, Clearfield M, Weis S, et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (results of AFCAPS/TexCAPS). JAMA. 198;279:1615–1622
  28. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) study group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  29. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  30. Post Coronary Bypass Graft Trial Investigators . The effects of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153–162
  31. Pitt B, Waters D, Brown WV, et al.  Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70–76
  32. Schwartz GG, Olsson AG. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL). Presented at the AHA Scientific Sessions 2000, Plenary Session XXII: Late-Breaking Trial Results. Nov 15th. 2000;
  33. Keogh A, MacDonald P, Kann A, et al.  Efficacy and safety of Pravastatin vs Simvastatin after cardiac transplantation. J Heart Lung Transplant. 2000;19:529–537
  34. Eich D, Thompson JA, Ko D, et al.  Hypercholesterolemia in long-term survivors of heart transplantation (an early marker of accelerated coronary artery disease). J Heart Lung Transplant. 1991;10:45–49
  35. Esper E, Glagov S, Karp RB, et al.  Role of hypercholesterolemia in accelerated transplant vasculopathy (results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation). J Heart Lung Transplant. 1997;16:420–435
  36. Rickenbacher PR, Kemna MS, Pinto FJ, et al.  Coronary artery intimal thickening in the transplanted heart (an in vivo intra-coronary ultrasound study of immunologic and metabolic risk factors). Transplantation. 1996;61:46–53
  37. Mehra MR, Ventura HO, Chamber R, et al.  Predictive model to assess risk for cardiac allograft vasculopathy (an intravascular ultrasound study). JACC. 1995;26:1537–1555
  38. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Valantine HA, Wiederhold V, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors (comparison of cyclosporine and azathioprine regimens). Circulation. 1989;80(suppl III):III-100–III-105
  39. Hosenpud JD, Bennett LE, Berkeley MK, et al.  The registry of the international society for heart and lung transplanta-tion: sixteenth annual report. 1999;18:611–626
  40. Cuthbert JA, Lipsky PE. Sterol metabolism and lymphocyte function (Inhibition of endogenous sterol biosynthesis does not prevent mitogen-induced human T-lymphocyte activation). J Immunol. 1980;124:2240–2246
  41. Cutts JL, Scallen TJ, Watson J, et al.  Role of mevalonic acid in the generation of natural killer cell cytotoxicity. J Cell Physiol. 1989;139:550–557
  42. Katznelson S, Wang XM, Chia D, et al.  The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 1998;17:335–340
  43. Cutts J, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin-2. J cell Physiol. 1990;145:244–252
  44. Cutts J, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase lovastatin. Int J Immunol. 1989;11:863–869
  45. Valantine HA, McCook O, Hunt SA, et al.  Interleukin-6 (potential role in accelerated transplant coronary artery disease). Circulation. 1994;90(suppl):I-94; [abstract]
  46. Awni WM, Heim-Duthoy K, Kasiske BL. Impact of lipoproteins on cyclosporine pharmacokinetic and biological activity in transplant patients. Transplant Proc. 1990;22:1193–1196
  47. Akhlaghi F, McLachlan AJ, Keogh AM, et al.  Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharm. 1997;44:537–542

PII: S1053-2498(01)00369-2

The Journal of Heart and Lung Transplantation
Volume 21, Issue 2 , Pages 204-210 , February 2002

Article Tools

* Image Usage & Resolution